Last reviewed · How we verify

Beta Blockers Carvedilol Phosphate — Competitive Intelligence Brief

Beta Blockers Carvedilol Phosphate (Beta Blockers Carvedilol Phosphate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta blocker (non-selective, with alpha-1 blocking activity). Area: Cardiovascular.

marketed Beta blocker (non-selective, with alpha-1 blocking activity) Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Beta Blockers Carvedilol Phosphate (Beta Blockers Carvedilol Phosphate) — Seoul National University Hospital. Carvedilol phosphate is a non-selective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors to reduce heart rate, blood pressure, and cardiac workload.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Beta Blockers Carvedilol Phosphate TARGET Beta Blockers Carvedilol Phosphate Seoul National University Hospital marketed Beta blocker (non-selective, with alpha-1 blocking activity) Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Carvedilol CR Carvedilol CR University of Florida marketed Non-selective beta-blocker with alpha-1 blocking activity Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Comparator: carvedilol Comparator: carvedilol Organon and Co marketed Beta-blocker with alpha-1 antagonist activity Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Carvedilol alone Carvedilol alone Taipei Veterans General Hospital, Taiwan marketed Beta-blocker with alpha-1 antagonist activity Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
CarVeDilol-SR (Slow Release) CarVeDilol-SR (Slow Release) Seoul National University Bundang Hospital marketed Beta-blocker with alpha-1 blocking activity Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Arotinolol Hydrochloride Arotinolol Hydrochloride Sumitomo Pharma (Suzhou) Co., Ltd. marketed Alpha-beta blocker Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Carvedilol SR 32mg, QD Carvedilol SR 32mg, QD Chong Kun Dang Pharmaceutical phase 3 Beta-blocker with alpha-1 blocking activity Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta blocker (non-selective, with alpha-1 blocking activity) class)

  1. Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Beta Blockers Carvedilol Phosphate — Competitive Intelligence Brief. https://druglandscape.com/ci/beta-blockers-carvedilol-phosphate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: